title: Improvement in adiposity with oligofructose is modified by antibiotics in obese rats.
abstract: Given the intimate link between gut microbiota and host physiology, there is growing interest in understanding the mechanisms by which diet influences gut microbiota and affects human metabolic health. Using antibiotics and the prebiotic oligofructose, which has been shown to counteract excess fat mass, we explored the gut microbiota-dependent effects of oligofructose on body composition and host metabolism. Diet-induced obese male Sprague Dawley rats, fed a background high-fat/sucrose diet, were randomized to one of the following diets for 6 wk: 1) high-energy control; 2) 10% oligofructose; 3) ampicillin; 4) ampicillin + 10% oligofructose; 5) ampicillin/neomycin; or 6) ampicillin/neomycin + 10% oligofructose. Combining oligofructose with ampicillin treatment blunted the decrease in adiposity seen with oligofructose. Although ampicillin did not affect total bacteria, ampicillin impeded oligofructose-induced increases in Bifidobacterium and Lactobacillus In contrast, the combination of ampicillin and neomycin reduced total bacteria but did not abrogate the oligofructose-induced decrease in adiposity. Oligofructose-mediated effects on host adiposity and metabolic health appear to be in part dependent on the presence of specific microbial species within the gut.-Bomhof, M. R., Paul, H. A., Geuking, M. B., Eller, L. K., Reimer, R. A. Improvement in adiposity with oligofructose is modified by antibiotics in obese rats.
authors.affiliation: Faculty of Kinesiology, University of Calgary, Calgary, Alberta Canada;
authors.forename: Marc R
authors.initials: MR
authors.lastname: Bomhof
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta Canada; and.
authors.forename: Heather A
authors.initials: HA
authors.lastname: Paul
authors.affiliation: Division of Gastroenterology, Department of Clinical Research, University Clinic for Visceral Surgery and Medicine, University of Bern, Bern, Switzerland.
authors.forename: Markus B
authors.initials: MB
authors.lastname: Geuking
authors.affiliation: Faculty of Kinesiology, University of Calgary, Calgary, Alberta Canada;
authors.forename: Lindsay K
authors.initials: LK
authors.lastname: Eller
authors.affiliation: Faculty of Kinesiology, University of Calgary, Calgary, Alberta Canada; Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta Canada; and reimer@ucalgary.ca.
authors.forename: Raylene A
authors.initials: RA
authors.lastname: Reimer
mesh_terms: D050154:Adiposity / Q000187:drug effects*; D000667:Ampicillin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001419:Bacteria / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D001786:Blood Glucose; D002149:Energy Intake; D005951:Glucose Tolerance Test; D008297:Male; D009355:Neomycin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009765:Obesity / Q000188:drug therapy*; D009844:Oligosaccharides / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D012336:RNA, Ribosomal, 16S; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000900:Anti-Bacterial Agents; D001786:Blood Glucose; D009844:Oligosaccharides; D012336:RNA, Ribosomal, 16S; C120489:oligofructose; D000667:Ampicillin; D009355:Neomycin
keywords: Bifidobacterium; Lactobacillus; gut microbiota; prebiotics